Aktis Oncology

As of June 30, 2026, cash, cash equivalents and marketable securities totaled about 517 million dollars against total liabilities of roughly 73 million dollars, with no financial debt. The 10-Q indicates at least 12 months of runway, and the 10-K notes that IPO proceeds combined with existing cash fund operations into 2029 under current plans.

TTM operating cash outflow is roughly mid-70 million dollars (H2 2025 plus H1 2026), and TTM FCF is negative, which is typical at this stage. Overall capital strength is high for a Phase 1 biotech, reducing near-term dilution risk.